Novel Applications of Anti-CD25 Antibody-Maytansine Conjugates

Expanding the therapeutic potential of anti-CD25 antibody-maytansine conjugates to novel applications in neurological disorders, cancer treatment, and diagnostic detection of CD25 expression

The original patent disclosed anti-CD25 antibody-maytansine conjugates for treating certain diseases, but its scope was limited to specific therapeutic areas. This inventive concept addresses the need for exploring new applications of this core technology to tackle unmet medical needs in diverse fields

The newly generated claims describe novel applications of anti-CD25 antibody-maytansine conjugates, including treating neurological disorders, preventing neuroinflammation, targeting CD25-expressing cancer cells, delivering conjugates through microfluidic devices, and detecting CD25 expression in cells. These applications leverage the conjugate's ability to modulate CD25 expression, reducing inflammation and promoting targeted therapy

The inventive concept's novelty lies in its expansion of the conjugate's therapeutic scope to previously unexplored areas, such as neurological disorders and diagnostic detection. The inventive step involves recognizing the potential of the core technology to address unmet needs in these fields and adapting it to these new applications

Alternative embodiments may include varying the maytansinoid structure, modifying the antibody's isotype or affinity, or using different conjugation chemistries. Variations could also involve combining the conjugate with other therapeutic agents or using it in conjunction with gene editing technologies

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, with potential applications in neurological disorders, cancer treatment, and diagnostic detection. The market for these applications is substantial, with growing demand for targeted and effective therapies